Pharmaceuticals & Biotechnology

IRulya Therapeutics Inc. CEO pay

Brendan Hannah, President. Fiscal year 2025, as reported to the SEC.

Total compensation

$1.3M

$1,263,075 for fiscal 2025: the Summary Compensation Table total, with stock and option awards at their grant-date value.

Definitive proxy statement, filed 2026-08-25SEC accession number 0001193125-26-364220

In context

The median chief executive among 465 Pharmaceuticals & Biotechnology companies was paid $2.2M. The middle half ranged from $1M to $4.9M.

Brendan Hannah's total is below that median.

See how your pay compares to IRulya Therapeutics Inc.'s peers

CEOSalary breaks this total into salary, bonus, stock and option awards, builds a peer set of comparable companies around it, and places your own package against them, with every figure cited to its filing.

Start a 3-day trial

Source: IRulya Therapeutics Inc.'s definitive proxy statement (SEC Form DEF 14A), Summary Compensation Table, fiscal year 2025. Figures are as reported by the company and are not adjusted or estimated. Context figures are from CEOSalary's snapshot of SEC filings as of 2026-10-28. Not financial, legal or compensation-consulting advice.